Biotics (Pre-, Pro-, Post-) and Uremic Toxicity: Implications, Mechanisms, and Possible Therapies

Overview

Journal Toxins (Basel)

Publisher MDPI

Specialty Toxicology

Date 2023 Sep 27

PMID 37755974

Authors

Laura Mitrea

Madalina Medeleanu

Carmen-Rodica Pop

Ancuta-Mihaela Rotar

Dan-Cristian Vodnar

Affiliations

Soon will be listed here.

Abstract

In recent years, more scientific data have pointed out the close connection between intestinal microbial community, nutritional habits, lifestyle, and the appearance of various affections located at certain anatomical systems. Gut dysbiosis enhances the formation and accumulation of specific metabolites with toxic potential that induce the appearance of kidney-associated illnesses. Intestinal microbes are involved in the degradation of food, drugs, or other ingested products that lead to the formation of various metabolites that end up in renal tissue. Over the last few years, the possibilities of modulating the gut microbiota for the biosynthesis of targeted compounds with bioactive properties for reducing the risk of chronic illness development were investigated. In this regard, the present narrative review provides an overview of the scientific literature across the last decade considering the relationship between bioactive compounds, pre-, pro-, and post-biotics, uremic toxicity, and kidney-associated affections, and the possibility of alleviating the accumulation and the negative effects of uremic toxins into the renal system.

Citing Articles

Future of Uremic Toxin Management.

Vanholder R, Snauwaert E, Verbeke F, Glorieux G Toxins (Basel). 2024; 16(11).

PMID: 39591217 PMC: 11598275. DOI: 10.3390/toxins16110463.

Efficacy of probiotics/synbiotics supplementation in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.

Liu C, Yang L, Wei W, Fu P Front Nutr. 2024; 11:1434613.

PMID: 39166132 PMC: 11333927. DOI: 10.3389/fnut.2024.1434613.

Unveiling the microbiota-metabolite-myocardium axis: a novel perspective on cardiovascular health.

Guo Z, Zhong Y, Zhou L, Xu P, Gao N, Lu J Front Microbiol. 2024; 15:1389311.

PMID: 38784809 PMC: 11112089. DOI: 10.3389/fmicb.2024.1389311.

The role of gut microbiota in intestinal disease: from an oxidative stress perspective.

Sun Y, Wang X, Li L, Zhong C, Zhang Y, Yang X Front Microbiol. 2024; 15:1328324.

PMID: 38419631 PMC: 10899708. DOI: 10.3389/fmicb.2024.1328324.

Probiotic co-supplementation with absorbent smectite for pancreatic beta-cell function in type 2 diabetes: a secondary-data analysis of a randomized double-blind controlled trials.

Savytska M, Kyriienko D, Zaychenko G, Ostapchenko D, Falalyeyeva T, Kobyliak N Front Endocrinol (Lausanne). 2024; 15:1276642.

PMID: 38405158 PMC: 10890794. DOI: 10.3389/fendo.2024.1276642.

References

Auguste B, Avila-Casado C, Bargman J . Use of vitamin D drops leading to kidney failure in a 54-year-old man. CMAJ. 2019; 191(14):E390-E394. PMC: 6453674. DOI: 10.1503/cmaj.180465. View

Rocchetti M, Di Iorio B, Vacca M, Cosola C, Marzocco S, di Bari I . Ketoanalogs' Effects on Intestinal Microbiota Modulation and Uremic Toxins Serum Levels in Chronic Kidney Disease (Medika2 Study). J Clin Med. 2021; 10(4). PMC: 7922022. DOI: 10.3390/jcm10040840. View

Rocchetti M, Cosola C, di Bari I, Magnani S, Galleggiante V, Scandiffio L . Efficacy of Divinylbenzenic Resin in Removing Indoxyl Sulfate and P-Cresol Sulfate in Hemodialysis Patients: Results From an In Vitro Study and An In Vivo Pilot Trial (xuanro4-Nature 3.2). Toxins (Basel). 2020; 12(3). PMC: 7150912. DOI: 10.3390/toxins12030170. View

Mele C, Remuzzi G, Noris M . Hemolytic uremic syndrome. Semin Immunopathol. 2014; 36(4):399-420. DOI: 10.1007/s00281-014-0416-x. View

Knauf F, Brewer J, Flavell R . Immunity, microbiota and kidney disease. Nat Rev Nephrol. 2019; 15(5):263-274. DOI: 10.1038/s41581-019-0118-7. View

Chao C, Lin S . Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins. Toxins (Basel). 2020; 12(12). PMC: 7767516. DOI: 10.3390/toxins12120812. View

Pecoits-Filho R, Abensur H, Betonico C, Machado A, Parente E, Queiroz M . Interactions between kidney disease and diabetes: dangerous liaisons. Diabetol Metab Syndr. 2016; 8:50. PMC: 4964290. DOI: 10.1186/s13098-016-0159-z. View

Antonelli G, Cappelli L, Cinelli P, Cuffaro R, Manca B, Nicchi S . Strategies to Tackle Antimicrobial Resistance: The Example of and . Int J Mol Sci. 2021; 22(9). PMC: 8125385. DOI: 10.3390/ijms22094943. View

Siew E, Abdel-Kader K, Perkins A, Greevy Jr R, Parr S, Horner J . Timing of Recovery From Moderate to Severe AKI and the Risk for Future Loss of Kidney Function. Am J Kidney Dis. 2019; 75(2):204-213. DOI: 10.1053/j.ajkd.2019.05.031. View

10.

Precup G, Vodnar D . Gut as a possible biomarker of diet and its eubiotic versus dysbiotic roles: a comprehensive literature review. Br J Nutr. 2019; 122(2):131-140. DOI: 10.1017/S0007114519000680. View

11.

Hall J, Jackson M, Farace G, Yerramilli M, Jewell D . Influence of Dietary Ingredients on Lean Body Percent, Uremic Toxin Concentrations, and Kidney Function in Senior-Adult Cats. Metabolites. 2019; 9(10). PMC: 6836002. DOI: 10.3390/metabo9100238. View

12.

Borges N, Barros A, Nakao L, Dolenga C, Fouque D, Mafra D . Protein-Bound Uremic Toxins from Gut Microbiota and Inflammatory Markers in Chronic Kidney Disease. J Ren Nutr. 2016; 26(6):396-400. DOI: 10.1053/j.jrn.2016.07.005. View

13.

Andre C, Bennis Y, Titeca-Beauport D, Caillard P, Cluet Y, Kamel S . Two rapid, accurate liquid chromatography tandem mass spectrometry methods for the quantification of seven uremic toxins: An application for describing their accumulation kinetic profile in a context of acute kidney injury. J Chromatogr B Analyt Technol Biomed Life Sci. 2020; 1152:122234. DOI: 10.1016/j.jchromb.2020.122234. View

14.

Yamamoto S, Fukagawa M . Uremic Toxicity and Bone in CKD. J Nephrol. 2017; 30(5):623-627. DOI: 10.1007/s40620-017-0406-x. View

15.

De Angelis M, Montemurno E, Piccolo M, Vannini L, Lauriero G, Maranzano V . Microbiota and metabolome associated with immunoglobulin A nephropathy (IgAN). PLoS One. 2014; 9(6):e99006. PMC: 4055632. DOI: 10.1371/journal.pone.0099006. View

16.

Pei M, Wei L, Hu S, Yang B, Si J, Yang H . Probiotics, prebiotics and synbiotics for chronic kidney disease: protocol for a systematic review and meta-analysis. BMJ Open. 2018; 8(7):e020863. PMC: 6067341. DOI: 10.1136/bmjopen-2017-020863. View

17.

Zheng D, Liwinski T, Elinav E . Interaction between microbiota and immunity in health and disease. Cell Res. 2020; 30(6):492-506. PMC: 7264227. DOI: 10.1038/s41422-020-0332-7. View

18.

Valim A, Carpes L, Nicoletto B . Effect of vegetarian diets on renal function in patients with chronic kidney disease under non-dialysis treatment: A scoping review. J Bras Nefrol. 2022; 44(3):395-402. PMC: 9518626. DOI: 10.1590/2175-8239-JBN-2021-0126. View

19.

Poh C, Seah X, Chong C, Ganesan I, Maiwald M, Nadua K . Renal Abscess in an Immunocompetent Child: Case Report and Literature Review. Glob Pediatr Health. 2021; 8:2333794X211022263. PMC: 8170294. DOI: 10.1177/2333794X211022263. View

20.

Jansen J, Jankowski J, Gajjala P, Wetzels J, Masereeuw R . Disposition and clinical implications of protein-bound uremic toxins. Clin Sci (Lond). 2017; 131(14):1631-1647. DOI: 10.1042/CS20160191. View